Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة ألفه للأدوية - ulfa pharma co. - sulpiride 50 mg - 50 mg

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

bayer new zealand limited - fluconazole 150mg; fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg fluconazole 150mg - canesten fluconazole capsule, given orally, is indicated for vaginal candidiasis.

Kanada - Kiingereza - Health Canada

vita health products inc - vitamin b1 (thiamine mononitrate); vitamin b2; nicotinamide; vitamin b6; vitamin b12; d-pantothenic acid (calcium d-pantothenate); folic acid; biotin - tablet - 50mg; 50mg; 50mg; 50mg; 50mcg; 50mg; .1mg; 50mcg - vitamin b1 (thiamine mononitrate) 50mg; vitamin b2 50mg; nicotinamide 50mg; vitamin b6 50mg; vitamin b12 50mcg; d-pantothenic acid (calcium d-pantothenate) 50mg; folic acid .1mg; biotin 50mcg - vitamin b complex

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - famciclovir - oral tablet - 250mg

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium - carprofen 50 mg - tablet - 50 mg - carprofen 50 mg - carprofen - dog

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية بيتا - beta drug store - liposomal amphotericin b 50 mg - 50 mg

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة التقدم للصناعات الدوائية - al-taqqadom pharmaceutical industries - hydralazine hcl 50 mg - 50 mg

Yordani - Kiingereza - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - vildagliptin 50 mg - 50 mg

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

viatris limited - naproxen 250mg;  ; naproxen 250mg - tablet - 250 mg - active: naproxen 250mg   excipient: lactose monohydrate magnesium stearate maize starch polysorbate 80 povidone purified talc quinoline yellow sodium starch glycolate active: naproxen 250mg excipient: lactose monohydrate magnesium stearate maize starch polysorbate 80 povidone purified talc sodium starch glycolate - indicated for its anti-inflammatory and analgesic action in the treatment of rheumatoid arthritis, osteoarthritis (degenerative arthritis), ankylosing spondylitis, juvenile rheumatoid arthritis, acute gout, acute musculoskeletal disorders, post-operative pain and dysmenorrhoea.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ciprofloxacin hydrochloride, quantity: 294.586 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 400 - ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.